Compared with healthy subjects, malaria causes a reduction in the mean oral clearance 27 (ACT) drug that is well tolerated and highly effective in the treatment of Plasmodium 37 falciparum malaria in Southeast Asia and Africa, with cure rates typically greater than 95% 38 following a standard 3-day course (8, 9, 15, 17). Despite its extensive use over the past 5 39 years, no data are available on the clinical pharmacokinetics of dihydroartemisinin in malaria 40 patients following treatment with the ACT. Few studies have investigated the 41 pharmacokinetics of piperaquine in malaria patients. The highly lipophilic drug exhibits 42 biphasic disposition kinetics, with a large apparent volume of distribution, low oral clearance 43 and a lengthy elimination half-life of about 3 to 4 weeks in malaria patients treated with 44
samples were stored at -25°C until transported on dry ice to Australia for drug analysis, 75 which was within 12 months of collection. 76
Plasma dihydroartemisinin concentrations were measured by liquid chromatography-77 tandem mass spectrometry, with a lower limit of quantification (LLOQ) of 1 ng/ml (2). The 78 overall precision of analysis for dihydroartemisinin, as defined by the percent coefficient of 79 variation of spiked samples was 6.3% at 1 ng/ml, 5.7% at 20 ng/ml, 4.6% at 200 ng/ml, and 80 6.6% at 750 ng/ml. The corresponding inaccuracy values were 1.3%, 1.5%, 0.7%, and 3.2%. 81
Plasma piperaquine concentrations were measured by a validated high-performance liquid 82 chromatography method, with a LLOQ of 5 ng/ml (11). The precision of the assay was 10.3% 83 at 10 ng/ml, 6.8% at 100 ng/ml, 6.7% at 500 ng/ml and 6.5% at 1,000 ng/ml. The 84 corresponding inaccuracy values were 11.1%, 2.8%, 0.8% and 0.5%. The ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine 91 was assessed by culturing malaria parasites in vitro in the presence of patients' plasma 92 samples collected after the last administration of Artekin using the method of Kotecka et al. 93 (10), with minor modifications. Briefly, patients' plasma samples (50 µl) were serially diluted 94 twofold on microtiter plates with drug-free human plasma. The in vitro drug susceptibility of 95 two lines of P. falciparum (chloroquine-sensitive D6 and chloroquine-resistant K1) to 96 dihydroartemisinin and piperaquine were determined in parallel with the patients' plasma 97 samples. Fifty microlitres of spiked drug solutions prepared in human plasma were serially 98 diluted twofold on microtiter plates using drug-free plasma. Inoculum (50 µl) was added to 99 total cell suspension (100 µl) contained 50% plasma in hypoxanthine-free plain LPLF-101 RPMI1640, with a final hematocrit of 2% and a parasitemia (>95% rings) of 1%. Tritiated-102 hypoxanthine incorporation was used to determine the extents to which parasite growth was 103 inhibited by different drug concentrations or dilutions of the patients' plasma during 48 h of 104 incubation. The inhibitory concentration (IC 90 for spiked drug samples) and inhibitory 105 dilution (ID 90 for patient plasma samples) were defined as the drug concentrations and the 106 number of dilutions of the patient plasma sample, respectively, that produced a 90% 107 inhibition of uptake of tritiated hypoxanthine by intraerythrocytic malaria parasites compared 108 to drug-free plasma samples (controls). 109
The mean (± standard deviation) age of the patients was 26. has also been reported for other antimalarial drugs such as mefloquine (7) and quinine (21) 139 during the acute phase of malaria. A likely explanation for the increase in bioavailability of 140 dihydroartemisinin in patients compared with healthy subjects is a decrease in hepatic 141 clearance of dihydroartemisinin due to malaria (1). Alpha-acid glycoprotein levels also 142 increase during acute malaria (16) and, similar to quinine, this may cause an increase in 143 binding of the protein-bound dihydroartemisinin, with a reduction in the apparent volume of 144 distribution of the drug (12). 145
In contrast to dihydroartemisinin, no data are available on the pharmacokinetics of 146 piperaquine given as a 3-day course of Artekin in healthy volunteers, and thus a comparison 147 between patients and healthy subjects could not be made to elucidate whether malaria affects 148 the disposition of piperaquine after Artekin administration. In the present study, the mean 149 on September 12, 2017 by guest http://aac.asm.org/ Downloaded from plasma concentration of piperaquine immediately before the last dose of Artekin was 131 150 ng/ml (range, 48 to 261 ng/ml). The mean C max of piperaquine was 568 ng/ml, which was 151 reached at 5.7 h after the final dose. The mean t 1/2 of piperaquine of 17.8 days in the 152
Vietnamese patients was less than 23 days in Cambodian adult patients (6) and 28 days in 153
Burmese and Karen patients (18). However, the estimated elimination half-life in the present 154 study might have been underestimated since piperaquine exhibits multiphasic elimination 155 (19), with blood sampling limited to 35 days after starting Artekin treatment. It has been 156 previously reported that the day 7 piperaquine concentration is an important determinant of 157 therapeutic response to Artekin and patients with levels below 30 ng/ml are more likely to 158 have a recurrence of malaria (14). All the patients had day 7 piperaquine concentrations 159 greater than 30 ng/ml, with a range of 37 to 118 ng/ml. antimalarial activity in the patients' plasma was solely due to piperaquine. At day 7 after 177 commencement of treatment, the mean number of dilutions of patients' plasma samples 178 required to produce an ID 90 had declined to <2 for both D6 and K1 lines. At day 28, the 179 patients' piperaquine concentrations (mean 24.9 ng/ml, range, 9.8 to 41.8 ng/ml) were 180 insufficient to completely kill either the D6 or K1 parasites. The clinical significance of the ex 181 vivo pharmacodynamic antimalarial activity profile of dihydroartemisinin-piperaquine is that 182 any mutant parasite that might survive physiological dihydroartemisinin and piperaquine 183 concentrations during the 3-day treatment period of Artekin will only have to engage the less 184 active piperaquine. Furthermore, because of piperaquine's prolong terminal half-life and 185 diminishing parasiticidal concentrations, selection pressure will be of concern for the potential 186 emergence of resistant parasites to piperaquine. 187
In conclusion, malaria infection affects the disposition of dihydroartemisinin, with a 188 reduction in both the apparent volume of distribution and apparent oral clearance of the drug. 
